(Total Views: 528)
Posted On: 11/03/2021 7:37:28 AM
Post# of 145875
Ohm wriote,
I'm still curious about how a portion of a study with 28 patients can show 36 times the increased survival. If 1 non-Leron patient survives, then 36 of the Leron patients would have to survive, but there are only 28 total.
Maybe they mean increased survival time rather than number of overall survivors. So if the non-Leron arm average patient survives say 2 months, the Leron arm patient survives an average of 72 months. Wait. That can't be true.
Can they PLEASE just show us the numbers? How many lived how long? How many had lower CTCs? How big is the subset they're measuring?
Okay, I'm being dense. If I were Craig I'd be telling you that I got 800 on my math boards.
Quote:
Overall Survival for the entire cohort of patients was 980%. The subset is patients that had lower initial CTCs or that had lower CTCs after using leronlimab. 75% of the patients from that subset showed a 3600% increase in overall survival. What I'd like to know is what is the percentage of patients in that subset compared to the total number of patients.
I'm still curious about how a portion of a study with 28 patients can show 36 times the increased survival. If 1 non-Leron patient survives, then 36 of the Leron patients would have to survive, but there are only 28 total.
Maybe they mean increased survival time rather than number of overall survivors. So if the non-Leron arm average patient survives say 2 months, the Leron arm patient survives an average of 72 months. Wait. That can't be true.
Can they PLEASE just show us the numbers? How many lived how long? How many had lower CTCs? How big is the subset they're measuring?
Okay, I'm being dense. If I were Craig I'd be telling you that I got 800 on my math boards.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)